CN Patent

CN121466055A — 肝内胆汁淤积性疾病的治疗

Assigned to CymaBay Therapeutics Inc · Expires 2026-02-06 · 0y expired

What this patent protects

本发明涉及通过利用赛乐达帕或其盐的疗法治疗肝内胆汁淤积性疾病。

USPTO Abstract

本发明涉及通过利用赛乐达帕或其盐的疗法治疗肝内胆汁淤积性疾病。

Drugs covered by this patent

seladelpar-lysine (SELADELPAR LYSINE)

Patent Metadata

Patent number: CN121466055A
Jurisdiction: CN
Classification: —
Expires: 2026-02-06
Drug substance claim: No
Drug product claim: No
Assignee: CymaBay Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.